USFDA grants Breakthrough Therapy Designation for Bristol Myers Squibb BMS-986278 for Progressive Pulmonary Fibrosis Ruchika Sharma26 Oct 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...
Bristol Myers Squibb Sotyktu long term data demonstrate durable efficacy, consistent safety for up to 3 years in moderate-to-severe Plaque Psoriasis Ruchika Sharma12 Oct 2023 12:50 PM ISTPrinceton: Bristol Myers Squibb has announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu...
Bristol Myers Squibb, Paradigm collaborate to build new model for clinical trials Ruchika Sharma11 Oct 2023 12:21 PM ISTColumbus: Paradigm has announced a collaboration with Bristol Myers Squibb to build a new end-to-end clinical trial operating model across...
Bristol-Myers Squibb to acquire Mirati Ruchika Sharma9 Oct 2023 3:30 PM ISTPrinceton: Bristol Myers Squibb and Mirati Therapeutics, Inc. have announced that they have entered into a definitive merger agreement under...
Perioperative regimen of neoadjuvant Opdivo, chemotherapy improves event free survival in Resectable Non-Small Cell Lung Cancer: Bristol Myers Squibb Ruchika Sharma25 Sept 2023 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced the Phase 3 CheckMate -77T trial has met its primary endpoint of improved event-free survival...
Bristol Myers plans to double experimental treatments to expand research pipeline Ruchika Sharma17 Sept 2023 3:00 PM ISTNew York: Bristol Myers Squibb has said it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies,...
Bristol Myers Squibb accused of illegal tactics to keep blood cancer drug Pomalyst monopoly in lawsuit Ruchika Sharma7 Sept 2023 1:30 PM ISTBristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on...
Bristol Myers Squibb gets USFDA nod for Reblozyl as first line treatment of Anemia in lower risk MDS Ruchika Sharma29 Aug 2023 11:09 AM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
Bristol Myers Squibb gets European Commission nod for Opdivo as adjuvant treatment for patients with completely Resected Stage IIB or IIC Melanoma Ruchika Sharma23 Aug 2023 11:23 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for Opdivo for adjuvant treatment for Melanoma Ruchika Sharma24 July 2023 11:22 AM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb, Evotec enter licence agreement within neuroscience partnership Ruchika Sharma16 July 2023 11:30 AM ISTEvotec receives a $ 40 m payment and is eligible to earn performance milestone payments, as well as tiered royalties up to low double-digit...
Bristol Myers Squibb bags European Commission nod for heart disease treatment Camzyos Ruchika Sharma27 Jun 2023 11:31 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg,...
